Coeptis–Z Squared Combination Reshapes Corporate Structure and Nasdaq Listing

According to a recent LinkedIn post from COEPTIS, Coeptis Therapeutics Holdings, Inc. has completed a business combination with Z Squared Inc. and spun out a majority of its biotechnology assets into a new private entity, Coeptis Therapeutics, Inc. The post notes that Z Squared’s public shares now trade on the Nasdaq Global Market under the ticker symbol ZSQR.

The company’s LinkedIn post suggests that despite this structural change, management intends to maintain its existing mission of advancing a portfolio of life‑saving therapies through clinical development. For investors, the transaction appears to separate public‑market exposure to the ZSQR platform from the privately held biotech assets, potentially altering the risk profile and valuation drivers.

The post also highlights an emphasis on continuing work with current collaborators while seeking new strategic partnerships across the industry. This focus on alliances could be relevant to investors as it may influence future capital needs, non‑dilutive funding opportunities, and the pace at which the therapy pipeline progresses toward commercialization.